Biologics Manufacturing Market Size Projected To Increase From $50.68 Billion To $106.07 Billion During The Forecast Period
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Biologics Manufacturing Market Growth Potential: How Will Market Size Change Through 2030?
In recent years, the biologics manufacturing market has experienced exponential growth. Its value is projected to increase from $42.04 billion in 2025 to $50.69 billion in 2026, representing a compound annual growth rate (CAGR) of 20.6%. This historical expansion has been driven by several factors, including the broadening of recombinant protein therapeutics, the early integration of mammalian cell culture systems, rising vaccine manufacturing capabilities, a greater reliance on outsourcing biologics production, and progress in purification technologies.
The biologics manufacturing sector is anticipated to experience substantial expansion over the coming years, with projections indicating it will reach a value of $106.08 billion by 2030, driven by a robust compound annual growth rate of 20.3%. This upward trajectory in the forecast period is primarily fueled by a heightened demand for customized biologic therapies, an uptick in capital allocated towards adaptable production methods, a broadening landscape for biosimilar development, an increased reliance on electronic bioprocessing technologies, and a concerted emphasis on achieving economical scale-up for high-volume outputs. Key developments shaping the future landscape encompass the widespread utilization of disposable bioprocessing equipment, a notable shift towards ongoing manufacturing techniques, a surge in requirements for large-quantity monoclonal antibody synthesis, the establishment of flexible modular facilities, and the refined incorporation of sophisticated process control systems.
Download A Free Sample Report For Comprehensive Market Insights:
Biologics Manufacturing Market Industry Drivers: What Is Driving Revenue Growth?
The increasing frequency of chronic illnesses is anticipated to drive expansion in the biologics manufacturing market moving forward. Chronic diseases are long-term health conditions that progress gradually and demand ongoing medical attention. Their growing occurrence can be partially attributed to sedentary lifestyles, since extended periods of sitting and reduced physical activity elevate the likelihood of ailments like heart disease and diabetes. Biologics manufacturing supports the management of chronic conditions through the development of specialized therapies, offering effective solutions for disorders such as diabetes, cancer, and autoimmune diseases. This approach lessens the overall disease burden by ensuring a reliable supply of high-quality biologic medications, which enhances patient outcomes and treatment effectiveness. To illustrate, in June 2024, the National Health Service, a UK government agency, reported that 3,615,330 individuals registered with a general practitioner were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, reflecting an 18% rise from 3,065,825 cases in 2022. Hence, the growing burden of chronic diseases is fueling advancement in the biologics manufacturing market.
Biologics Manufacturing Market Segments: Where Are The Largest Growth Opportunities?
The biologics manufacturing market covered in this report is segmented –
1) By Mode of Manufacturing: Contract Manufacturing, In-House Manufacturing
2) By Modality: Monoclonal Antibodies (mAbs), Biosimilar And Recombinant Proteins, Vaccines (recombinant/mRNA/Viral), Cell And Gene Therapies, Ribonucleic Acid-Based Therapeutics
3) By Disease Indication: Oncology, Autoimmune Disorders, Infectious Diseases, Neurological Disorders, Other Disease Indications
Subsegments:
1) By Contract Manufacturing: Mammalian Cell-Based Production, Microbial Fermentation Production, Cell-Free Protein Synthesis, Hybrid Manufacturing Systems
2) By In-House Manufacturing: Mammalian Cell Culture Production, Microbial Expression Systems, Continuous Bioprocessing, Single-Use Technology Production
Biologics Manufacturing Market Growth Trends: What Is Influencing The Future Outlook?
Key players in the biologics manufacturing sector are placing a strong emphasis on creating cutting-edge solutions, specifically integrated contract development and manufacturing organization (CDMO) platforms, with the aim of improving comprehensive biologics development, boosting production effectiveness, and streamlining supply networks across various treatment categories. Such a platform is essentially a complete system that merges development, manufacturing, and distribution services under one unified structure. As an example, in June 2023, Catalent Inc., a contract development and manufacturing company headquartered in the US, unveiled an upgraded version of its OneBio Suite designed for the coordinated development, manufacturing, and distribution of diverse biologic modalities. This enhanced suite delivers a full-scale integrated biologics CDMO platform capable of handling antibodies, cell and gene therapies, and mRNA-based products. Additionally, it covers the entire value chain from initial development all the way through fill-finish and packaging, facilitated by a single agreement and harmonized project oversight, which results in shorter development cycles, better scalability, and smooth integration into global supply chains.
Biologics Manufacturing Market Major Participants And Competitive Dynamics
Major companies operating in the biologics manufacturing market are Johnson & Johnson, F. Hoffmann La-Roche Ltd., Pfizer Inc, AbbVie Inc., Eli Lilly and Company, Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., LG Life Sciences Ltd., Novo Nordisk A/S, Amgen Inc., FUJIFILM Holdings Corporation, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Lonza Group Ltd., Intas Pharmaceuticals Ltd., Samsung Biologics Co. Ltd., Fareva SA, Celltrion Inc., Evotec SE
Access The Complete Biologics Manufacturing Market Report:
Biologics Manufacturing Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the biologics manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
